Lactic acidemia is one manifestation of the mitochondrial diseases caused by pathogenic mutant mitochondrial DNA (mtDNA). However, little is known about its chronic effects in the progression of mitochondrial disease phenotypes. To obtain experimental evidence on this point, we used trans-mitochondrial model mice (mito-mice) heteroplasmic for wild-type and deleted mtDNA (DmtDNA). Mito-mice carrying predominantly DmtDNA showed mitochondrial respiration defects and the resultant disease phenotypes, including lactic acidemia; they also showed a decrease in mitochondrial biogenesis regulated by the peroxisome proliferative activated receptor gamma, coactivator 1 alpha (PGC1a)-mediated pathway, such as the expression of mitochondrial transcription factor A and mtDNA-encoded gene products and the control of mtDNA content. When the accelerated lactate production of these mito-mice was pharmacologically inhibited by sodium dichloroacetate (DCA), the decrease in mitochondrial biogenesis improved, thus leading to the relaxation of mitochondrial respiration defects and extension of life span. These results showed that chronic overproduction of lactate caused by metabolic adaptation in mitochondrial diseases further deconditioned mitochondrial function. Mitochondrial respiration defects in mitochondrial diseases are therefore induced not only directly by the presence of mutant mtDNA, but also by the chronic lactic acidemia. Our in vivo study also suggested that inhibition of chronic lactic acidemia is a potential strategy for treating some mitochondrial diseases.
INTRODUCTION
In the past, lactate has largely been considered a dead-end product of glycolysis in the state of hypoxia. Today, however, lactate is being proposed as an active metabolite both within and between cells, playing important roles in muscle fatigue and contraction, wound repair and regeneration, spermatogenesis and astrocyte-neuron interaction (1) . The regulation of lactate levels in the body and its cells therefore needs to be in delicate balance. In cells with mitochondrial dysfunction, as well as in cancer cells, by contrast, it is well known that chronic overproduction of lactate occurs (2) (3) (4) .
Mitochondria are organelles capable of producing 90% or more of all the energy made in body by oxidative phosphorylation. Mammalian mitochondria have multiple copies of the genome as mtDNA that is replicated and expressed within the organellar systems (2, 5) . Mammalian mtDNA encodes 13 polypeptides that are essential subunits of complexes I, III, IV (cytochrome c oxidase: COX) and V for oxidative phosphorylation; it also encodes 22 tRNAs and 2 rRNAs that are needed for the translation of these 13 polypeptides. Many reports have shown that the accumulation of pathogenic mtDNAs with large-scale deletions or point mutations in the cells and tissues induces electron transport chain defects, leading to a wide variety of mitochondrial diseases (2, 5) . In such mitochondrial diseases, lactic acidemia, which is indicative of chronic overproduction of lactate in cells with mitochondrial respiratory defects, is a typical clinical phenotype (2, 5) . It occurs because pyruvate is inadequately utilized at the level of reoxidation of reduced cofactors through the electron transport chain, and the glycolytic pathway is † E.O. and K.N. contributed equally to this study. * To whom correspondence should be addressed. Tel: +81 298536694; Fax: +81 298536614; Email: knakada@biol.tsukuba.ac.jp (K.Z.); Tel: +81 298536650; Fax: +81 298536614; Email: jih45@biol.tsukuba.ac.jp (J.-I.H.) consequently accelerated to produce ATP without mitochondrial respiration.
In the pathogenesis of mitochondrial diseases, it has been generally accepted that the main reason for mitochondrial respiration defects is accumulation of pathogenic mutant mtDNAs, because all the gene products encoded by mammalian mtDNA are required for mitochondrial respiratory function. It has therefore been considered that the most effective treatment strategy is to eliminate mutant mtDNA molecules preferentially, or to dilute the molecules to below the threshold proportion for the expression of disease phenotypes. It has been confirmed by nuclear transplantation experiments in animal models that this strategy is effective as a prenatal treatment (6) . However, it is not possible to apply this strategy in patients who have already contracted mitochondrial diseases. In in vitro studies using human cell models carrying pathogenic mutant mtDNAs, several unique concepts by which mutant mtDNA molecules are digested by mitochondrialtargeted restriction enzyme or zinc-finger nuclease have been proposed as a treatment strategy (7, 8) . It has been also reported that ketogenic treatment is effective for heteroplasmic shift to lower levels of DmtDNA in human cells (9) . At present, however, mitochondrial diseases caused by mutant mtDNAs remain largely untreatable.
In light of the importance of lactate in cellular, regional and whole-body metabolism (1), it is possible that chronic lactic acidemia as a metabolic adaptation in mitochondrial diseases is itself pathogenic in terms of the progression of mitochondrial disease phenotypes, and that the inhibition of accelerated lactic production could become a treatment strategy in patients with mitochondrial diseases. Gene therapy introducing an additional pathway for the direct oxidation of lactate has resulted in an improvement of disease phenotypes in Caenorhabditis elegans with disease-causing missense mutations in a nuclear-encoded subunit of Complex I (10). Trans-mitochondrial mice carrying pathogenic mtDNAs (mito-mice) are useful models to demonstrate the pathogenicity of lactic acidemia in mitochondrial diseases (11) .
Previously, we succeeded in generating mito-mice with either a 4696 bp deletion from nucleotide position 7759 of the tRNA Lys gene to position 12 454 of the ND5 gene (DmtDNA) or wild-type mtDNA (11) (Supplementary  Material, Fig. S1A ). The DmtDNA molecule in mito-mice is similar to pathogenic mutant mtDNA with the 'common deletion' in human mitochondrial diseases (12) , and mito-mice carrying more than 80% DmtDNA show mitochondrial respiration defects and the resultant mitochondrial disease phenotypes, such as low body weight, lactic acidemia, myopathy, heart block, male infertility, impairment of spatial remote memory, anemia and renal failure (11,13 -16) . Our study was designed to use these mito-mice to confirm the effects of chronic lactic acidemia in the pathogenesis of mitochondrial diseases. We show here that lactic acidemia could affect mitochondrial biogenesis [e.g. the expression of transcription factor A (TFAM) and mtDNA-encoded gene products and the control of mtDNA content], resulting in further deterioration of mitochondrial diseases. Inhibition of chronic lactic acidemia would be a potential strategy for treating some mitochondrial diseases, although there is a biological difference between human and mouse cases.
RESULTS

Inhibition of lactic acidemia and its beneficial effects in mito-mice
Before the experiment, we analyzed the occurrence of lactic acidemia in mito-mice aged 4.5-6.5 months (n ¼ 54) and carrying 26.3-84.2% DmtDNA. Because DmtDNA loads are approximately uniform throughout most tissues of individual mito-mice (11, 17) , we estimated the DmtDNA load in the tissues of the mito-mice from tail samples. The mito-mice began to express lactic acidemia from when they carried more than 50% DmtDNA in their tails (Fig. 1A) . We therefore concluded that mito-mice could be used as models to examine the involvement of lactic acidemia in the pathogenesis of mitochondrial diseases.
After examining the proportions of DmtDNA in the tail samples, we paired mito-mice carrying almost the same loads of DmtDNA (n ¼ 40, 20 pairs) ( Table 1 ). It has been reported that lactic acidemia can be inhibited pharmacologically with DCA, because the DCA stimulates pyruvate dehydrogenase complex and accelerates the oxidation of glucose, lactate and pyruvate to acetyl-coenzyme A by inhibiting pyruvate dehydrogenase kinase (18) . Once daily, we gave DCA (50 mg/kg weight) orally to one of the pair of mice (DCA group) and phosphate-buffered saline (PBS) orally to the other (PBS group). The mito-mouse in each pair that carried the greater DmtDNA load was always given the DCA treatment. The blood lactate levels of the two groups (pairs [16] [17] [18] [19] [20] were almost identical (8.2 + 1.0 mmol/l in the DCA group and 7.8 + 1.9 mmol/l in the PBS group) before the administration of DCA or PBS started; however, these levels were definitely higher than those of normal B6 mice (5.3 + 0.6 mmol/l, n ¼ 5) (Fig. 1B) . Lactic acidemia in the PBS group increased gradually over time (Fig. 1B) , because the proportion of DmtDNA increased with time (11, 17) (Supplementary Material, Fig. S1B ). In contrast, the blood lactate levels in the DCA group clearly recovered to normal level and were very well maintained by DCA administration (Fig. 1B) . These results showed that DCA was effective for decreasing and controlling blood lactate levels in the mito-mice.
Next, we compared the life spans of the two groups (n ¼ 30, 15 pairs) carrying 54.1-84.2% DmtDNA in their tails before DCA or PBS administration started (Table 1 ). In 12 pairs that carried 54.1-73.5% DmtDNA in their tails (pairs 1-6 and 8-13) and in which we examined life span, the DCA-treated mice survived, whereas the PBS-treated mice in the pairs died as a result of the expression of mitochondrial diseases (Fig. 1C) . The mean life span of the DCA group was about 2.0 months longer (range 27 to 140 days) than that of the PBS group (Fig. 1C and D) . Elongation of life span was especially marked in mito-mice carrying no more than 74% DmtDNA (Fig. 1D) ; these mice looked quite normal when DCA administration was started. Elongation of life span was not observed in the DCA-treated mice of the two pairs carrying 82.1 and 84.2% DmtDNA (pairs 14 and 15), respectively; signs of mitochondrial diseases were already apparent in these mice before DCA administration. These results indicated that the degree of lactic acidemia was related to the initial pathogenic process in mitochondrial diseases.
Finally, we evaluated the biological quality in the DCA group in terms of body weight (pairs 16 -20) , food consumption, locomotion and mating ability (pairs 1, 3, 7, 9 and 10). Maintenance of body weight and food consumption in the DCA group were better than in the PBS group, although these results did not reach the ranges found in normal B6 mice ( Fig. 1E and F ). In the footprint assay, which is a rough measure of locomotion activity, mice in the PBS group took significantly fewer steps than those in the DCA group, although the two groups originally showed normal results in the assay before the onset of mitochondrial diseases (Fig. 1G) . Previously, we reported that it was difficult to find out copulation plugs (evidence of successful mating) in normal female mice cohabiting with male mito-mice carrying large amounts of DmtDNA were cohabitated with the females (14) . Consistent with this result, in a mating assay using the PBS group, we observed a significant reduction in the prevalence of copulation plugs compared with that in the B6 mice. In contrast, the prevalence of copulation plugs recovered in the mating assay using the DCA group (Fig. 1H ), although it was still significantly lower than in the B6 mice. These results suggested that the maintenance of quality of life was extended by the inhibition of lactic acidemia.
Side effects of DCA administration in mito-mice
Because DCA can cause peripheral nerve toxicity (19), we examined whether mito-mice given DCA suffered neuronal In order to accurately evaluate the effect of DCA, changes of blood lactate level and body weight ( Fig. 1B and E) were analyzed by using data from pairs 16-20 that were used for post-mortem studies, although blood lactate levels and body weights of all mice were measured.
side effects. A significant reduction in handgrip (one of the signs of neuropathy) compared with those in both the B6 and the PBS mice was observed in testing 16 weeks after the start of DCA administration (pairs 1, 3, 7, 9 and 10) (Fig. 1I ). In the hotplate test, a significant extension in latency of the reaction to heat stimulation was seen in the DCA group compared with both the B6 and the PBS groups (Fig. 1J) , indicating some failure of motor nerve reactivity and the peripheral senses. Thus, DCA administration induced peripheral nerve abnormalities in the mito-mice.
Pathophysiological effects of lactic acidemia in mito-mice
In our previous works, most mito-mice carrying DmtDNA beyond the pathogenic threshold for mitochondrial respiration defects showed disease phenotypes in various tissues (11, 13) . Mitochondrial respiration defects and the resultant disruption with cell death in the renal tissues were particularly marked, and thus renal failure was the main cause of death of mitomice (11, 13) . We therefore anticipated that the enhanced survival in the DCA group was the result of suppression of renal abnormalities. To verify this hypothesis, we compared the levels of blood urea nitrogen (BUN)-a clinical marker of renal failure-between the two groups. After 12 weeks of treatment, the BUN level of the DCA group was significantly lower than that in the PBS group (pairs [16] [17] [18] [19] [20] , although it was still significantly higher than in the B6 mice, suggesting improvement of renal failure or improved preservation of renal function in the DCA group ( Fig. 2A) . Next, we sacrificed five pairs of mice (pairs 16-20) (Table 1) , in which the mitochondrial diseases in the PBS group had reached an advanced stage, and we compared the histological features of the kidneys in the two groups. In the PBS group, dilatation of the cortical tubules, with casts, was prominent, and there were significantly more terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL)-positive nuclei than in normal B6 mice or DCA mice ( Fig. 2B and C) . In contrast, the histological features in the DCA group were similar to those in normal B6 mice (Fig. 2B) . The proportion of TUNEL-positive nuclei was significantly lower in the DCA group than in the PBS group, although it was still significantly higher than in the B6 mice and slight dilatation of the lumina of the renal tubules was apparent ( Fig. 2B and C) .
The histological differences between the two groups suggested that the inhibition of lactic acidemia was likely to delay the onset of renal abnormality. However, it was possible that the degree of accumulation of DmtDNA in the kidneys of the DCA mice was in fact less than the pathogenic threshold for the expression of renal failure. We therefore estimated the proportions of DmtDNA in the kidneys of mice in the DCA and PBS groups. The average proportions of DmtDNA in the kidneys were 89.5 + 1.8% in the DCA group (n ¼ 5, pairs [16] [17] [18] [19] [20] and 85.3 + 4.3% in PBS group (n ¼ 5, pairs [16] [17] [18] [19] [20] . It was therefore clear that the proportion in the DCA group was sufficient for the expression of renal failure, because the kidneys of mice in the PBS group, which carried a lower load of DmtDNA than the mice in the DCA group, showed disrupted histology, as mentioned above.
Considering the fact that the accumulation of large amounts of DmtDNA reliably induces mitochondrial respiration defects in various tissues and cells (11, 13) , one would expect mitochondrial respiration defects to be induced in the kidneys of not only the PBS group, but also the DCA group. However, it was possible that the improvement in the mitochondrial disease phenotypes in the DCA group was caused by the acceleration of the biochemical flux to the TCA cycle, because although the DCA can inhibit lactate production it can also accelerate the flux from pyruvate to acetyl-coenzyme A (18) . If it was the case, the DCA group would not show recovery from the defects of mitochondrial respiration complex's activity induced by accumulation of DmtDNA beyond the pathogenic threshold. To test this, we examined the histochemical activity of COX, a mitochondrial respiration complex, in the two experimental groups (pairs 19 and 20). As expected, there was less brown staining (indicative of COX activity) in the kidneys of mice from the PBS group. Surprisingly, many of the renal tubules of DCA-group mice possessed COX activity, even when these tissues carried a higher load of DmtDNA than those of mice in the PBS group (Fig. 2B) . Moreover, biochemical COX activity in the DCA group was significantly higher than in the PBS group (pairs [16] [17] [18] (Fig. 2D) , although it was significantly lower than in the B6 mice. The same results were obtained from the analyses of hearts (Fig. 2B-E) ; the average proportions of DmtDNA in hearts were 81.6 + 2.8% in the DCA group (n ¼ 5, pairs [16] [17] [18] [19] [20] and 77.9 + 3.6% in PBS group (n ¼ 5, pairs [16] [17] [18] [19] [20] . To confirm recovery from the mitochondrial respiration defects, we examined the relative ATP contents in various tissues from both groups. Compared with the PBS group, the kidneys, hearts, skeletal muscles (M. soleus) and testes from the DCA group showed significant recovery from the decrease in relative ATP content (Fig. 2F) . These results indicated that the inhibition of lactic acidemia could help repair the mitochondrial respiration defects caused by the accumulation of DmtDNA beyond the pathogenic threshold. In the brain, there was no significant difference in relative ATP content between the two groups, and the relative ATP content of the DCA group was in fact (non-significantly) lower than that of the PBS group (Fig. 2F) , probably because of the neuronal side effects of DCA.
Molecular regulation for repair of mitochondrial respiration defects by inhibition of lactic acidemia
In mito-mice carrying predominant amount of DmtDNA, the main reason for the mitochondrial respiration defects is the shortage of six tRNA genes, rather than the seven structural genes lost in DmtDNA (Supplementary Material, Fig. S1A ). In this case, an increase in mtDNA gene expression or/and mtDNA content could enable sufficient supply of these six tRNAs, resulting in normal mitochondrial translation.
PGC1a is a positive regulatory factor for mitochondrial biogenesis that controls mitochondrial gene expression and mtDNA content (20) . In addition, a calcium-regulated signal pathway controls mitochondrial biogenesis upstream of PGC1a (21) . We therefore examined the expression of calcium/calmodulindependent protein kinase II (CaMKII) protein and PGC1a mRNA in the PBS and DCA groups. In immunohistochemical staining, the PBS group showed a decrease in the positive signal for CaMKII protein in the kidney and heart, compared with agematched controls, whereas increased positive signals were observed in the kidney and heart of DCA-group mice (Fig. 3A) .
PGC1a mRNA expression was significantly lower in the PBS group than in age-matched controls, whereas significant recovery of the decreased expression of PGC1a mRNA expression was observed in the DCA group (Fig. 3B) . To clarify whether the recovery of PGC1a-mediated pathway in the DCA group was responsible for the regulation of mitochondrial gene expression and mtDNA content, we first examined the mRNA levels of TFAM in the two groups, because TFAM encoded by nuclear DNA regulates mitochondrial gene expression and mtDNA content (22) . The levels of TFAM mRNA in the kidneys and hearts of PBS-group mice were significantly lower than those of normal B6 mice. In the DCA group, there was a significant recovery of the decreased TFAM mRNA level (Fig. 3B) .
We then examined the mRNA levels of the 16S rRNA and cytochrome c oxidase II (MTCO2) encoded by mtDNA. Expression of the mRNA for 16S rRNA was significantly lower in the kidneys and hearts of PBS-group mice than in those of age-matched controls; the same was true for MTCO2 mRNA in the kidneys, although the result did not reach statistical significance in the hearts. In the DCA group, expression of the mRNA for 16S rRNA recovered significantly to normal or greater levels in the kidneys and hearts; the same was true for MTCO2 mRNA in the kidneys, although again the recovery did not reach statistical significance in the hearts (Fig. 3B) . Finally, we examined mtDNA content in the two groups (pairs [16] [17] [18] [19] [20] . In the kidneys, hearts and testes (but not the skeletal muscles or brains), the mtDNA content in the PBS group was significantly lower than that of agematched controls. The mtDNA copy number in the DCA group was 1.2 -1.5 times that in the PBS group (Fig. 3C) .
DISCUSSION
It has been well known that lactic acidemia is induced in mitochondrial diseases caused by pathogenic mutant mtDNAs, but it has remained unclear whether the presence of lactic acidemia is a result of the pathogenesis of mitochondrial diseases or a problem in itself. Here, we treated mito-mice showing the onset of lactic acidemia with DCA, a specific lactic acidlowering agent (18) , to clarify the involvement of lactic acidemia in pathogenesis of mitochondrial diseases. Mito-mice in which the expression of lactic acidemia was suppressed by DCA showed recovery from mitochondrial respiration defects (Fig. 2B, D and E) . Consequentially, improvement of mitochondrial disease phenotypes was observed in these mitomice, and the life spans of the mice were extended with general retention of quality of life (Fig. 1C -H) . Therefore, our in vivo study succeeded in showing that the pathogenesis of mitochondrial diseases might be associated with a combination of the primary mitochondrial respiration defect and lactic acidemia-induced chronic deconditioning.
Possible mechanism of lactic acidemia-induced chronic deconditioning in the pathogenesis of mitochondrial diseases may be as follows. Because lactate can bind Ca 2+ (23) , overproduction of lactate would disturb the calcium signaling in various cells, thus reducing the levels of CaMKII protein (Fig. 3A) . This reduction in CaMKII protein production would, in turn, negatively regulate PGC1a-mediated mitochondrial biogenesis processes (e.g. the expression of TFAM-and mtDNA-encoded gene products and the control of mtDNA content). As a result, mitochondrial respiratory function would further deteriorate; this deterioration would be additional to the primary mitochondrial respiration defects induced by the mutated mtDNAs.
In skeletal muscle tissues, a transient increase in cellular lactate levels with fatigue has positive effects on mitochondrial biogenesis through a CaMKII-dependent PGC1a pathway (24) . In contrast, our results showed that the chronic increase in cellular lactate levels because of mitochondrial respiration defects has negative effects on mitochondrial biogenesis. Thus, mitochondrial biogenesis might be reversibly controlled, depending on the length of time for which cellular lactate continues to be produced. This potential mechanism for the control of mitochondrial biogenesis by lactate levels requires further investigation.
The DCA group clearly showed recovery of mitochondrial respiration defects (Fig. 2B, D and E) , even when mice in this group carried greater loads of DmtDNA than those in the PBS group, which showed serious mitochondrial respiration defects. In mito-mice, mitochondrial respiratory function can be maintained quite normally until the DmtDNA accumulates to more than 80%, because the wild-type mtDNA can supply all tRNAs, including the six tRNAs that are lost in the DmtDNA, for mitochondrial translation. In contrast, when the accumulated DmtDNA is over 80%, mitochondrial translation may become limiting because of the depletion of sufficient tRNAs transcribed solely from the wild-type mtDNA. Thus, the translation phase is shifted from complementation to competition, in accordance with the proportions of DmtDNA and wild-type mtDNA molecules. In short, more than 20% wildtype mtDNA is needed to keep mitochondrial respiration at a normal level in mito-mice. The recovery of TFAM expression in the DCA group was important to our understanding of recovery from mitochondrial respiration defects in this group, because TFAM is mitochondrial transcription, translation and stabilizing factors of mtDNA (25) . Acceleration of TFAM expression in the DCA group could induce an increase in the abundance of transcripts of mtDNA-encoded genes, probably restoring the supply of the six tRNAs lost in the DmtDNA. As an additional effect, the recovery of TFAM expression could induce the alteration of mtDNA contents. The DCA group had mtDNA contents 1.2 -1.5 times those of the PBS group (Fig. 3C ). An increase of 1.2-1.5 times in the mtDNA content of a mito-mouse carrying 80% DmtDNA gives theoretical proportions of wild-type mtDNA of 24-30% and of DmtDNA of 96-120%. Therefore, we considered that the DCA group carried theoretically 24-30% wild-type mtDNA in absolute terms. Our previous studies have shown that mitomice carrying 70 -75% DmtDNA (i.e. 25 -30% wild-type mtDNA) express slight mitochondrial respiration defects but no marked mitochondrial disease phenotypes (11, (13) (14) (15) . The recovery of TFAM expression may therefore have enabled the relaxation of mitochondrial disease phenotypes and extension of life span in the DCA group.
In a recent study in a uniform cohort of MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and strokelike episodes) patients carrying the A3243G mutation, the potential beneficial effects of DCA were outweighed by peripheral nerve toxicity (19) . In contrast, our mouse studies suggested that DCA treatment was effective in suppressing the progression of mitochondrial disease phenotypes. There are two possible reasons why DCA treatment showed no beneficial effects in the MELAS cohort. The first is that the start of DCA administration might have been too late to demonstrate its potential effects. Consistent with the results in the MELAS cohort, we did not observe a significant extension of life span when DCA was given to mito-mice carrying 80% or more DmtDNA that showed evidence of the onset of mitochondrial disease phenotypes at the time treatment began (Fig. 2C and D) . On the other hand, administration of DCA to mito-mice that carried 54-74% DmtDNA and that developed clinical lactic acidosis extended their life spans. These results indicated that the inhibition of lactic acidemia with DCA was effective in the early, but not the late, stages in the pathogenesis of mitochondrial diseases. The second possibility is differences in the types of mutated mtDNA molecule. Most MELAS patients have an A3243G point mutation in tRNA Leu(UUR) gene of mtDNA (26) . The A3243G mutation in MELAS patients generates tRNA Leu(UUR) without a taurinecontaining modified uridine at the anticodon wobble position (27) , and the unmodified tRNA Leu(UUR) can induce translational abnormalities of all 13 structural gene products coded in the mtDNA (28) . Even if the TFAM-mediated mtDNA gene expression and mtDNA content are increased by DCA treatment in MELAS patients, the unmodified tRNA Leu(UUR) content is similarly increased. In the case of mito-mice, however, the increased TFAM-mediated mtDNA gene expression and mtDNA content could supply the six tRNA genes lost by large-scale deletion. This may be why DCA treatment did not have a therapeutic effect in the MELAS patients.
In light of the side effects of DCA in MELAS patients, DCA cannot be used as an effective drug in patients with mitochondrial diseases (19) . Our in vivo study in mito-mice, however, demonstrated the pathogenicity of lactic acidemia and its involvement in the pathogenesis of mitochondrial diseases. It also suggested that the inhibition of lactic acidemia would be effective in delaying the deterioration of symptoms in some patients with mitochondrial diseases, although there are biological differences between such disorders in humans and mice. It is therefore necessary to screen novel lactatelowering chemicals with little or no toxicity. Mito-mice would be useful models for these chemical screenings. Recently, it has been reported that a drug-like small molecule FX11 can be decreased cellular production of lactate (29) . The FX11 might be one candidate for an alternative to DCA, if it shows little or no toxicity.
MATERIALS AND METHODS
Mice
Mice carrying DmtDNA (mito-mice) were generated by introducing DmtDNA from cultivated cells into the zygotes of B6 strain mice by using cell fusion techniques, as described in previously (11) . Male mito-mice (4.5 -6.0 months old) carrying 26.3-84.2% DmtDNA (n ¼ 54) and age-matched male B6 mice (n ¼ 5) as normal controls were used for blood lactate analysis. Of 54 mito-mice, 40 carrying 54.1-84.2% DmtDNA were used for subsequent studies. For mating assay, female B6 mice (n ¼ 5) were used. Information of all mito-mice examined is summarized in Table 1 .
Estimation of DmtDNA proportions
Proportions of wild-type mtDNA and DmtDNA were determined by a real-time PCR technique, as described previously (6) . The proportion of DmtDNA in mito-mice was deduced from total DNA samples of the tail, kidney and heart.
Measurement of mitochondrial DNA content
Total mtDNA content was estimated by a real-time PCR technique using a Quantitect Cyber Green Kit (Qiagen, Hilden, Germany). To compare the total mtDNA content, nuclear gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was measured as an internal control and DDCt was used. The primer set specific for both wild-type and DmtDNA was 5 ′ -CCCACGATCAACTGAAGCAGCAA-3 ′ and 5 ′ -ACCGT TTGTTTGTTGAAATATT-3 ′ . The primer set specific for GAPDH was 5
′ -AACGACCCCTTCATTGAC-3 ′ and 5 ′ -TCC ACGACATACTCAGCAC-3 ′ .
Administration of DCA or PBS
Forty male mito-mice (4.5 -6.0 months old) carrying 54.1 -84.2% DmtDNA were used, and mice carrying almost the same DmtDNA proportions were paired (20 pairs). Once daily, DCA (50 mg/kg weight) (Sigma, MO, USA) or PBS solution was administered orally, beginning when the blood lactate levels of the mice exceeded those of normal B6 mice; the mouse of each pair that was given the DCA was considered part of the DCA group, and that given the PBS was part of the PBS group. The two groups of mice were weighted and blood lactate levels were monitored during the administration period.
Measurement of blood lactate and BUN
For the measurement of blood lactate and BUN concentrations, blood was collected from the tail vein. Lactate concentration was measured with an automatic blood lactate test meter Lactate Pro (ARKRAY, Kyoto, Japan). BUN was measured with a Urea N B test (Wako Pure Chemical, Osaka, Japan) in accordance with the manufacturer's protocol.
Measurement of ATP content
For measurement of the ATP content of mouse tissues, tissues were homogenized and lysed with 100 ml of ATP extracting buffer (TOYO B-Net Co., Ltd., Tokyo, Japan) and then placed directly into the chamber of a luminometer (Berthold Technologies, Bad Wildbad, Germany). Light emission was recorded after the addition of 100 ml of luciferin-luciferase solution (TOYO B-Net Co., Ltd.). Luminescent signals were detected by a luminometer.
Analysis of COX activity
Histological and biochemical analyses for COX activity were carried out as described previously (11, 13, 15) . In the histological analysis, cryosections (10 mm thick) of renal and cardiac tissues were used.
Histological analysis
Tissue samples were fixed in 10% formaldehyde solution. Paraffin sections (6 ml) of the kidneys were stained with Mayer's hematoxylin and with eosin solution. To detect apoptotic nuclei, TUNEL staining was performed with an in situ apoptosis detection kit (TAKARA Bio, Shiga, Japan) in accordance with the manufacturer's protocol. Stained sections were counterstained with Mayer's hematoxylin solution. The number of TUNEL-positive nuclei was randomly counted in five fields (346 mm × 432 mm) in each section. For immunohistochemistry, sections were reacted with an anti-a-CaMKII antibody (BD Biosciences, CA, USA); this was followed by reaction with a secondary antibody Alexa Fluor 488 conjugated goat anti-mouse IgG (Invitrogen, CA, USA).
Behavioral evaluations
To evaluate mating ability, a DCA-or PBS-group mouse or an age-matched B6 mouse was allowed to cohabit with a female B6 mouse until a plug was found in the female; the female with the plug was then exchanged for a new female. The procedure was repeated five times with each male mouse. A hotplate test was used to evaluate sensitivity to painful stimuli. Mice were placed on a hotplate at 508C and the time to the first response (jumping, foot shake or paw lick) was measured. Handgrip was measured by using a Grip Strength Meter (Columbus Instruments, OH, USA); three sequential trials were performed for the test. To evaluate locomotion activity, black ink was placed on both hind limbs of the mice and the mice were then placed on white paper (15.5 cm × 25.5 cm). The total number of footprints in 10 s was counted.
Measurement of cDNA levels
Total RNAs from renal and cardiac tissues were extracted by Isogen RNA isolation kit (Nippon Gene, Tokyo, Japan) and subjected to DNase I treatment. Then, reverse transcription to cDNA was performed using Oligo(dT) 12 -18 ′ . The PCR products were separated by electrophoresis on 3% agarose gels, stained with ethidium bromide and then visualized UV transillumination. The signal intensity was quantified with ImageJ software (National Institutes of Health, MD, USA).
Statics
Data were analyzed with Student's t-test. All values are means + SD, and values with P , 0.05 were considered to differ significantly.
